Crescent Reports Q4 Revenue of $10.8M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy CBIO?
Reports Q4 revenue $10.8M vs .$0 last year. "2025 was a transformational year for Crescent and our efforts to deliver next generation therapies that can improve outcomes for people living with cancer. We expanded our pipeline and accelerated our efforts to deliver best-in-class novel combinations through our exciting partnership with Kelun-Biotech," said Joshua Brumm, chief executive officer of Crescent. "We now have our Phase 1/2 ASCEND clinical trial underway for CR-001, which is positioned to be an immuno-oncology backbone in the treatment of solid tumors. Three more trials are on track to initiate this year, including the first Phase 1/2 ADC combination trial with CR-001. We are rapidly advancing toward multiple clinical data readouts beginning in the first quarter of 2027 and with our recent private placement, we are well funded to deliver on these milestones."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CBIO
Wall Street analysts forecast CBIO stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.190
Low
22.00
Averages
28.20
High
35.00
Current: 11.190
Low
22.00
Averages
28.20
High
35.00
About CBIO
Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Crescent Biopharma Partners with Kelun-Biotech to Expand Oncology Pipeline
- Strategic Partnership: Crescent has established a collaboration with Sichuan Kelun-Biotech to develop CR-001 (a PD-1 x VEGF bispecific antibody) and multiple antibody-drug conjugates (ADCs), which is expected to accelerate the expansion of its oncology pipeline and significantly enhance market competitiveness.
- Clinical Trial Progress: The ASCEND global clinical trial has commenced to evaluate CR-001's efficacy in various advanced solid tumors, with preliminary clinical data expected to be reported in Q1 2027, further validating its potential as an immuno-oncology backbone.
- Funding Support: Crescent completed a $185 million private placement, providing financial backing for key clinical data readouts and ensuring operational funding through 2028, thereby strengthening its R&D capabilities in cancer treatment.
- Increased R&D Spending: Research and development expenses reached $138.1 million in 2025, a significant increase from 2024, reflecting the company's ongoing investment in projects like CR-001 and CR-002, aimed at rapidly advancing innovative therapies.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: Crescent Biopharma approved the grant of 24,600 stock options to two non-executive employees on February 17, 2026, as part of its 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent to enhance the company's competitiveness in cancer treatment.
- Option Details: The granted options have a 10-year term with an exercise price of $9.33 per share, complying with Nasdaq listing rules, ensuring that employees receive attractive economic incentives upon accepting employment, thereby promoting stability within the company.
- Vesting Arrangement: Each employee's options will vest one-fourth on the first anniversary of their start date, with one-forty-eighth vesting monthly thereafter, ensuring continuous service with Crescent to receive long-term incentives, thus enhancing employee loyalty and motivation.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing various innovative therapies, including a PD-1 x VEGF bispecific antibody, with the goal of rapidly developing potentially transformative treatments for a range of solid tumors.
See More
Crescent Biopharma Launches CR-001 Clinical Trial for Solid Tumors
- Trial Launch: Crescent Biopharma has initiated the ASCEND clinical trial globally to evaluate CR-001, a PD-1 x VEGF bispecific antibody for various solid tumors, with plans to enroll 290 patients, showcasing the company's innovative potential in cancer treatment.
- Data Reporting Expectations: The company anticipates reporting proof-of-concept data from the ASCEND trial in Q1 2027, including safety and preliminary antitumor activity, aimed at providing robust data support for the further development of CR-001.
- Multiple Indication Assessment: The ASCEND trial is designed to comprehensively assess the clinical profile of CR-001 in both first-line and previously treated patients, intending to drive the company's development strategy across multiple indications and enhance its market competitiveness.
- Strategic Collaboration Expansion: Crescent has entered into a strategic collaboration with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., granting exclusive rights to research and commercialize CR-001 in Greater China, further expanding its influence in the Asian market.
See More
Crescent Biopharma to Participate in Biotech Summit 2026
- Management Participation: Crescent Biopharma is scheduled to participate in the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026, in New York, showcasing its latest advancements in cancer therapies, which is expected to attract investor attention and enhance the company's visibility.
- Live Webcast Availability: The event will be webcast live on the company's website, with a replay accessible for 90 days post-event, enhancing interaction with investors and increasing transparency and trust.
- Pipeline Overview: Crescent Biopharma's clinical-stage pipeline includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs), aiming to rapidly advance cancer treatments that could transform existing therapeutic paradigms.
- Company Vision: Crescent Biopharma is committed to becoming a world-leading oncology company, leveraging multiple modalities and combination regimens to rapidly advance potentially transformative therapies for a range of solid tumors, demonstrating its strategic ambition in the biotech sector.
See More
Analysts Bullish on Century Communities, Target Price Set at $92
- Century Communities Rating: Analyst James McCanless initiated coverage on Century Communities Inc (NYSE:CCS) with a Market Outperform rating and a price target of $92, indicating significant upside from Tuesday's close of $66.26, reflecting confidence in the company's growth prospects.
- Alumis Inc Rating: Chardan Capital analyst Janani Sundararajan initiated coverage on Alumis Inc (NASDAQ:ALMS) with a Buy rating and a price target of $37, suggesting a 41% upside from Tuesday's close of $26.06, showcasing optimism about its business outlook.
- Credo Technology Rating: Rosenblatt analyst Mike Genovese initiated coverage on Credo Technology Group Holding Ltd (NASDAQ:CRDO) with a Neutral rating and a price target of $170, indicating potential upside from the current price of $153.22, reflecting a cautious view on its market performance.
- Crescent Biopharma Rating: Guggenheim analyst Brad Canino initiated coverage on Crescent Biopharma Inc (NASDAQ:CBIO) with a Buy rating and a price target of $35, representing a 150% upside from Tuesday's close of $13.98, indicating strong confidence in its future growth potential.
See More
Crescent Biopharma Grants 129,626 Stock Options to Attract Talent
- Options Grant: Crescent Biopharma's Board approved the grant of 129,626 stock options to three non-executive employees as part of the 2025 Employment Inducement Incentive Award Plan, aimed at attracting key talent and enhancing team stability.
- Incentive Structure: The options have an exercise price of $13.21 per share, aligning with the closing price on December 15, 2025, ensuring that employees can benefit financially as the company performs well.
- Vesting Schedule: Options will vest one-fourth on the first anniversary of the employee's start date, with one-forty-eighth vesting monthly thereafter, ensuring long-term employee commitment through continuous service with Crescent.
- Strategic Aim: By implementing such incentive measures, Crescent Biopharma aims to build an efficient oncology team to rapidly advance innovative therapies like its PD-1 x VEGF bispecific antibody, further solidifying its market position in the biotechnology sector.
See More
Crescent Biopharma Partners with Kelun-Biotech to Expand Oncology Pipeline
- Strategic Partnership: Crescent has established a collaboration with Sichuan Kelun-Biotech to develop CR-001 (a PD-1 x VEGF bispecific antibody) and multiple antibody-drug conjugates (ADCs), which is expected to accelerate the expansion of its oncology pipeline and significantly enhance market competitiveness.
- Clinical Trial Progress: The ASCEND global clinical trial has commenced to evaluate CR-001's efficacy in various advanced solid tumors, with preliminary clinical data expected to be reported in Q1 2027, further validating its potential as an immuno-oncology backbone.
- Funding Support: Crescent completed a $185 million private placement, providing financial backing for key clinical data readouts and ensuring operational funding through 2028, thereby strengthening its R&D capabilities in cancer treatment.
- Increased R&D Spending: Research and development expenses reached $138.1 million in 2025, a significant increase from 2024, reflecting the company's ongoing investment in projects like CR-001 and CR-002, aimed at rapidly advancing innovative therapies.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: Crescent Biopharma approved the grant of 24,600 stock options to two non-executive employees on February 17, 2026, as part of its 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent to enhance the company's competitiveness in cancer treatment.
- Option Details: The granted options have a 10-year term with an exercise price of $9.33 per share, complying with Nasdaq listing rules, ensuring that employees receive attractive economic incentives upon accepting employment, thereby promoting stability within the company.
- Vesting Arrangement: Each employee's options will vest one-fourth on the first anniversary of their start date, with one-forty-eighth vesting monthly thereafter, ensuring continuous service with Crescent to receive long-term incentives, thus enhancing employee loyalty and motivation.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing various innovative therapies, including a PD-1 x VEGF bispecific antibody, with the goal of rapidly developing potentially transformative treatments for a range of solid tumors.
See More
Crescent Biopharma Launches CR-001 Clinical Trial for Solid Tumors
- Trial Launch: Crescent Biopharma has initiated the ASCEND clinical trial globally to evaluate CR-001, a PD-1 x VEGF bispecific antibody for various solid tumors, with plans to enroll 290 patients, showcasing the company's innovative potential in cancer treatment.
- Data Reporting Expectations: The company anticipates reporting proof-of-concept data from the ASCEND trial in Q1 2027, including safety and preliminary antitumor activity, aimed at providing robust data support for the further development of CR-001.
- Multiple Indication Assessment: The ASCEND trial is designed to comprehensively assess the clinical profile of CR-001 in both first-line and previously treated patients, intending to drive the company's development strategy across multiple indications and enhance its market competitiveness.
- Strategic Collaboration Expansion: Crescent has entered into a strategic collaboration with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., granting exclusive rights to research and commercialize CR-001 in Greater China, further expanding its influence in the Asian market.
See More
Crescent Biopharma to Participate in Biotech Summit 2026
- Management Participation: Crescent Biopharma is scheduled to participate in the Guggenheim Emerging Outlook: Biotech Summit on February 12, 2026, in New York, showcasing its latest advancements in cancer therapies, which is expected to attract investor attention and enhance the company's visibility.
- Live Webcast Availability: The event will be webcast live on the company's website, with a replay accessible for 90 days post-event, enhancing interaction with investors and increasing transparency and trust.
- Pipeline Overview: Crescent Biopharma's clinical-stage pipeline includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs), aiming to rapidly advance cancer treatments that could transform existing therapeutic paradigms.
- Company Vision: Crescent Biopharma is committed to becoming a world-leading oncology company, leveraging multiple modalities and combination regimens to rapidly advance potentially transformative therapies for a range of solid tumors, demonstrating its strategic ambition in the biotech sector.
See More
Analysts Bullish on Century Communities, Target Price Set at $92
- Century Communities Rating: Analyst James McCanless initiated coverage on Century Communities Inc (NYSE:CCS) with a Market Outperform rating and a price target of $92, indicating significant upside from Tuesday's close of $66.26, reflecting confidence in the company's growth prospects.
- Alumis Inc Rating: Chardan Capital analyst Janani Sundararajan initiated coverage on Alumis Inc (NASDAQ:ALMS) with a Buy rating and a price target of $37, suggesting a 41% upside from Tuesday's close of $26.06, showcasing optimism about its business outlook.
- Credo Technology Rating: Rosenblatt analyst Mike Genovese initiated coverage on Credo Technology Group Holding Ltd (NASDAQ:CRDO) with a Neutral rating and a price target of $170, indicating potential upside from the current price of $153.22, reflecting a cautious view on its market performance.
- Crescent Biopharma Rating: Guggenheim analyst Brad Canino initiated coverage on Crescent Biopharma Inc (NASDAQ:CBIO) with a Buy rating and a price target of $35, representing a 150% upside from Tuesday's close of $13.98, indicating strong confidence in its future growth potential.
See More
Crescent Biopharma Grants 129,626 Stock Options to Attract Talent
- Options Grant: Crescent Biopharma's Board approved the grant of 129,626 stock options to three non-executive employees as part of the 2025 Employment Inducement Incentive Award Plan, aimed at attracting key talent and enhancing team stability.
- Incentive Structure: The options have an exercise price of $13.21 per share, aligning with the closing price on December 15, 2025, ensuring that employees can benefit financially as the company performs well.
- Vesting Schedule: Options will vest one-fourth on the first anniversary of the employee's start date, with one-forty-eighth vesting monthly thereafter, ensuring long-term employee commitment through continuous service with Crescent.
- Strategic Aim: By implementing such incentive measures, Crescent Biopharma aims to build an efficient oncology team to rapidly advance innovative therapies like its PD-1 x VEGF bispecific antibody, further solidifying its market position in the biotechnology sector.
See More
